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SUMMARY
Imatinib is the standard of care for patients with advanced metastatic gastrointestinal stromal
tumors (GIST), and is also approved for adjuvant treatment in patients at substantial risk of
relapse. Studies have shown that maximizing benefit from imatinib depends on long-term
administration at recommended doses. Pharmacokinetic (PK) and pharmacodynamic factors,
adherence, and drug–drug interactions can affect exposure to imatinib and impact clinical
outcomes. This article reviews the relevance of these factors to imatinib’s clinical activity and
response in the context of what has been demonstrated in chronic myelogenous leukemia (CML),
and in light of new data correlating imatinib exposure to response in patients with GIST. Because
of the wide inter-patient variability in drug exposure with imatinib in both CML and GIST, blood
level testing (BLT) may play a role in investigating instances of suboptimal response, unusually
severe toxicities, drug–drug interactions, and suspected non-adherence. Published clinical data in
CML and in GIST were considered, including data from a PK substudy of the B2222 trial
correlating imatinib blood levels with clinical responses in patients with GIST. Imatinib trough
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plasma levels <1100 ng/mL were associated with lower rates of objective response and faster
development of progressive disease in patients with GIST. These findings have been supported by
other analyses correlating free imatinib (unbound) levels with response. These results suggest a
future application for imatinib BLT in predicting and optimizing therapeutic response.
Nevertheless, early estimates of threshold imatinib blood levels must be confirmed prospectively
in future studies and elaborated for different patient subgroups.
Keywords
Gastrointestinal neoplasms; Sarcoma; Tyrosine kinase inhibitors; Pharmacokinetics;
Pharmacodynamics; Drug monitoring; Dose-response relationship
INTRODUCTION
The introduction of imatinib mesylate (Gleevec®, Glivec®; Novartis Pharma AG, Basel,
Switzerland) marked an important clinical step forward in the care of patients with advanced
gastrointestinal stromal tumors (GIST). Imatinib, arguably the archetype for tyrosine kinase
inhibitor (TKI) therapeutics, has provided unsurpassed long-term responses in clinical trials,
extending survival almost three-fold compared with treatment prior to targeted therapy.1–3
Still, pitfalls to achieving the best possible clinical outcome in individual patients exist, and
maximizing long-term clinical benefit from imatinib may result from dose optimization and
strategies to attain proper adherence to therapy. Drug concentrations appear to be associated
with outcomes in GIST: low trough levels of imatinib are associated with significantly
shorter times to progression.4,5
This review will examine current data on factors that affect exposure to and clinical
outcomes with imatinib, including pharmacokinetic (PK) parameters and their variability
among individual patients; the pharmacodynamics (PD) of imatinib, including its
mechanism of action in inhibiting KIT and PDGFRα; drug–drug interactions; and
adherence. Data on the potential utility of blood level testing (BLT) with respect to each of
these factors will also be discussed.
IMATINIB IN GIST
GIST, with a yearly incidence of 10 to 20 cases per million inhabitants, comprise the most
common sarcoma of the intestinal tract, accounting for 82% of all gastrointestinal (GI)
mesenchymal neoplasms.6 The development of GIST is generally driven by mutations in the
KIT gene or, less commonly, the PDGFRA gene. More than half of GIST cases are found in
the stomach; other sites include the small intestine (35%), colorectum (<5%), and rarely the
esophagus, omentum, or mesentery.6 GIST are found more often in adults older than 50
years of age, with a slightly greater preponderance in males than females in some series.6,7
Imatinib is a small-molecule TKI indicated for the treatment of adult patients with KIT-
positive, advanced, unresectable malignant GIST as well as for adjuvant treatment of adult
patients at substantial risk of disease recurrence following complete tumor resection.8 Trials
have demonstrated an unprecedented efficacy and tolerability of imatinib in patients with
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advanced metastatic GIST.2,3 Neoadjuvant imatinib has also been shown to be safe and
efficacious in helping to achieve complete resection (R0, negative margins) and/or to reduce
surgical morbidity.9,10 Adjuvant imatinib was shown to improve recurrence-free survival
(RFS) following primary resection.11 Major treatment guidelines from the European Society
of Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN)
have each been updated to reflect these advances.12,13
Overview of considerations for optimizing imatinib treatment
The recommended starting dose for first-line imatinib in advanced GIST is 400 mg daily,
although dose escalation to 800 mg daily is recommended for many patients who progress
on imatinib.12,13 Phase III studies comparing 400 with 800 mg daily in advanced disease
have shown a progression-free survival (PFS) benefit with imatinib 800 mg daily for tumors
with KIT exon 9 mutations.14,15
Continuous imatinib dosing is important in the management of advanced GIST. The French
Sarcoma Group BFR14 study demonstrated that interruption of imatinib is associated with
increased risk of relapse, even in patients who have achieved complete remission.16 These
results in GIST contrast with recent findings in chronic myelogenous leukemia (CML), in
which it may be possible to discontinue imatinib treatment after a sustained complete
molecular response has been achieved, particularly in patients pretreated with interferon.17
Current ESMO and NCCN guidelines recommend that imatinib be continued indefinitely in
advanced disease until disease progression, at which time using dose escalation of imatinib
followed by sunitinib as indicated.12,13
PHARMACOKINETICS OF IMATINIB
The PK of imatinib have been assessed in studies in healthy subjects and in population PK
studies in more than 500 patients with GIST or CML.3,18–22 Imatinib is rapidly and
completely absorbed from the GI tract, achieving a peak plasma concentration (Cmax) within
2 to 4 hours following oral administration.21 Imatinib’s bioavailability is independent of
food intake, and the mean absolute bioavailability of imatinib is 98%.19,21 Imatinib
undergoes rapid and extensive distribution into tissues, with minimal penetration into the
central nervous system.21 In the circulation, imatinib is approximately 95% bound to plasma
proteins, principally albumin and α1-acid glycoprotein (AGP).22,23 Imatinib undergoes
metabolism in the liver via the cytochrome P (CYP) 450 enzyme system, with CYP3A4
being the primary isoenzyme involved.21 The N-desmethyl metabolite CGP74588 is the
major circulating active metabolite.21,24 The elimination half-life for imatinib is
approximately 16 to 18 hours.21,22
Pharmacokinetics in GIST Patients
The PK properties of imatinib in patients with CML and GIST are similar, with a few subtle
differences. The Cmax of imatinib at steady state in patients with GIST has been measured at
2.9 µg/mL compared with 2.3 µg/mL in patients with CML.18,25 Also, the rate of clearance
for imatinib is approximately 8% lower in patients with GIST than in patients with CML.22
Small differences in PK properties between GIST and CML patient populations might be
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attributable to factors that affect drug absorption or elimination, such as differences in liver
function (advanced GIST patients commonly have liver metastases), or anatomical or
functional abnormalities of the GI tract due to GISTrelated surgery on the liver, stomach, or
intestines.21,26 An alternate explanation may be differences in CYP isoenzymes that result in
variable rates of drug metabolism or drug interactions, especially at the CYP3A4 level.27
Imatinib PK were evaluated in a substudy of the first 73 of 147 randomized patients with
advanced GIST who were enrolled in the Phase II B2222 trial.5 Large inter-patient
variability in imatinib plasma exposure (coefficient of variation 40–50%) was observed
(Table 1). These findings are consistent with results previously reported for patients with
CML and GIST.20,22 Figure 1 provides a graphic representation of this variability, described
by percentile curves obtained from previously published PK data from patients with GIST.22
Such variability in exposure underscores the potential impact of imatinib plasma
concentrations on clinical outcomes in both GIST and CML.
Population PK analyses in patients with advanced GIST have identified several variables as
significant covariates for imatinib exposure and clearance, including white blood cell
(WBC) counts, body weight, and granulocyte count, as well as AGP, albumin, and
hemoglobin levels.22,28,29 Additionally, a recent study found the ABCB1 (MDR1) genotype,
coding for the P-glycoprotein (P-gp) drug transporter, to be a significant covariate for
imatinib clearance.30 Some of these variables may change or normalize with improvement
in the disease, thus having an impact on drug exposure and clearance. In fact, it has been
shown that a trend exists toward increased imatinib clearance over time.28,29 However, a
progressive decline in adherence might be a confounding factor. In the B2222 PK substudy,
the only two significant PK covariates for imatinib clearance and volume of distribution
(Figure 2) were plasma albumin level and WBC, with age, gender, and body weight exerting
only minimal effects.5 A retrospective analysis conducted by Nolden and colleagues in 142
patients with metastatic GIST found that imatinib plasma levels ranged from 256 to 4582
ng/mL, with a first quartile cutoff of 851 ng/mL.31 Imatinib plasma levels were shown to
correlate with age, gender, imatinib dose, and response by Choi criteria. In addition, patients
with KIT exon 9 mutations treated with a higher dose of imatinib had higher plasma levels
of imatinib, and had a PFS similar to patients harboring KIT exon 11 mutations.
Imatinib tissue levels in GIST
Limited PK and PD data on imatinib tissue levels in GIST are available. Tissue distribution
of imatinib occurs by both active and passive diffusion. Imatinib appears to be a substrate
for some cellular influx transporters (OCT1 and OATP1A2) and efflux transporters (P-gp
and breast cancer resistance protein).32–39 Results from in vitro studies demonstrate
involvement of both OCT1 and P-gp in active transport processes of imatinib, mediating the
influx and efflux of the drug in cancer cells.40 Recent findings indicate that expression of
OCT1 in CML cells plays a role in determining clinical response to imatinib; higher
pretreatment OCT1 expression has been correlated with improved rates of complete
cytogenetic response.38
The rationale for increasing the dose of imatinib in select progressing patients rests in the
potential for higher drug concentrations to overcome drug efflux mechanisms. Alternatively,
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dose escalation may result in raising drug levels to within the therapeutic range conferred by
secondary resistance mutations.41
Imatinib free concentrations
Recent results have demonstrated the importance of free drug concentrations of imatinib, the
pharmacologically active fraction not bound by albumin or AGP, in considering exposure.
The free area under the PK curve (AUC) for imatinib, which can either be measured directly
or as the correction of the total drug concentration for binding to AGP, provides a valuable
surrogate for cellular drug exposure.22 Higher free AUC of imatinib has been shown to be a
significant predictor of therapeutic response in patients with GIST.42
CORRELATING IMATINIB EXPOSURE WITH RESPONSE IN CML
Among patients with CML, significant correlations between imatinib trough plasma levels
(Cmin) and cytogenetic and molecular responses have been found.43–45 In a PK/PD
subanalysis of results from the International Randomized Interferon versus STI571 (IRIS)
study, including 351 patients with chronic-phase (CP) CML, imatinib plasma Cmin levels
higher than 1000 ng/mL correlated significantly with improved rates of cytogenetic and
molecular responses.44 In the Tyrosine Kinase Dose Optimization Study (TOPS), evaluation
of the effect of imatinib 400 mg bid compared with imatinib 400 mg daily in previously
untreated patients with newly diagnosed CP CML showed that imatinib trough plasma levels
were proportional to dose and stable over time despite high interpatient variability.46
Patients with imatinib Cmin in the lowest quartile showed a lower major molecular response
rate (MMR) at 12 months, whereas patients in the highest Cmin quartile showed a higher
frequency of all grades of some adverse events.46
Another analysis pooled data from patients with newly diagnosed and previously untreated
Ph+ CP CML from both the IRIS and TOPS trials. This study confirmed that higher steady-
state imatinib levels correlated with better complete cytogenetic response (CCyR) and
MMR, but also resulted in more Grade 3 and 4 treatment-related toxicities.47 These results
suggested a possible role for imatinib blood or plasma level testing in evaluating – as well as
optimizing – responses in patients with CML.44,46,47 In the case-control study by Singh and
colleagues, mean plasma levels in non-responders were shown to be significantly lower than
those in responders (413 vs 1380 ng/mL, respectively; P=0.002) in 40 patients with CML
(20 responders and 20 non-responders to imatinib).45 Based on these data, a subsequent
receiver operating curve (ROC) analysis showed that a trough plasma level threshold higher
than only 560 ng/mL could be sufficient to reduce the incidence of resistance (determined
however only on a short-term basis).48 Another recent study reported conflicting results,
however, with no correlation found between imatinib levels and CCyRs at 1 year or between
imatinib levels and major molecular responses after a median of 1298 days of therapy.49
Additional studies in various CML patient populations, confirming the imatinib
concentration-response relationship, continue to emerge in the literature.50,51
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CORRELATING IMATINIB EXPOSURE WITH RESPONSE IN GIST
In GIST, important findings are emerging from studies examining the relationship between
imatinib PK and response to treatment.5,42,52 Correlations between free drug levels and side
effects have also been observed.29,42 In the PK substudy of B2222, correlations were based
on imatinib Cmin at steady state. Imatinib AUC, Cmax, and Cmin values were highly inter-
correlated.5 However, there was less variability in Cmin over time compared with Cmax, and
Cmin was more easily monitored than AUC. Figure 3 shows the distribution of patients by
imatinib Cmin level (divided into quartiles) at steady state (Day 29). This analysis revealed
that patients with imatinib Cmin above the lowest quartile threshold, 1100 ng/mL, had higher
rates of objective response, with improved disease control and increased clinical benefit
(Table 2). Overall, responding patients (complete response [CR], partial response [PR], or
stable disease [SD]) had markedly higher median imatinib Cmin (1446 ng/mL) than non-
responders (1155 ng/mL), with significantly longer PFS associated with higher imatinib
Cmin as well (Table 2). No significant differences in median overall survival (secondary
endpoint) were found between different imatinib Cmin groups, perhaps due to the small
numbers of patients in each group.5 Combined, these findings suggest a minimal plasma
threshold is necessary to achieve and maintain clinical response with imatinib in patients
with GIST.
Results from the PK analysis conducted by Widmer and colleagues in Switzerland that
examined the relationship between imatinib free plasma levels and response similarly
demonstrated the importance of adequate drug exposure in achieving and maintaining
therapeutic response, as well as a significant correlation between imatinib exposure and
incidence of adverse events.42 A prior analysis in 58 patients with GIST or CML evaluated
imatinib PK using a non-linear mixed-effects population model (NONMEM®); free drug
exposures (expressed as AUC) were estimated.22 Among those patients with GIST, higher
imatinib-free AUC was a significant predictor of therapeutic response (odds ratio ±standard
error [SE]: 2.6±1.1; P=0.026 by logistic regression). This PK model also allows the
extrapolation of random sampling results (i.e. obtained from blood samples taken at any
time after the last drug dose) in terms of free Cmin using a Bayesian maximum a posteriori
estimation.53
Correlating imatinib exposure and response by mutational subtype
Imatinib response in GIST varies based on the type of activating mutation(s)
present.2,15,54,55 Mutational analysis of tumors from the large European Organisation for
Research and Treatment of Cancer–Australasian Phase III trial, comparing response and
survival following either standard-dose (400 mg daily) or high-dose (800 mg daily) imatinib,
found that the presence of KIT exon 11 mutation was the strongest predictor of response and
disease stabilization in patients with GIST.15 Tumors with KIT exon 9 mutation were
associated with significantly poorer PFS on standard-dose therapy, which was not observed
in KIT exon 11 or wild-type (WT) tumors.15 Similar results were reported from the North
American Southwest Oncology Group S0033 Phase III trial, in which KIT exon 9 and WT
genotypes predicted poorer response and shorter time to progression versus KIT exon 11
mutations; there was some evidence of improved response in those with exon 9 mutant
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genotypes who received high-dose imatinib.55 The MetaGIST analysis of both Phase III
studies of imatinib indicates that imatinib 800 mg daily significantly improved PFS in high-
risk patients whose GIST harbored a KIT exon 9 mutation in contrast to those that harbored
other mutations.14
In the B2222 PK substudy, presence of KIT exon 11 mutation predicted improved rates of
clinical benefit with imatinib exposure greater than 1100 ng/mL.5 In 39 patients with KIT
exon 11 mutations evaluated by Cmin quartile (as shown in Table 3), patients in the upper
quartiles had significantly higher rates of overall objective clinical benefit: 100% achieved
either CR, PR, or SD compared with 67% (6/9) for those in quartile (Q) 1 (P=0.0001
between Q1 and Q2–Q4, Chi-square test).5 There were too few patients with KIT exon 9
mutations to be able to draw any conclusions with respect to this subgroup. Results from the
Swiss analysis by Widmer and colleagues found the strongest associations between free
plasma concentrations and response among patients whose tumors harbored KIT exon 9
mutations or WT KIT.42 In a more recent analysis, the relationship between extrapolated
free Cmin and response in GIST was shown to be especially relevant in patients whose
tumors contain a KIT exon 9 mutation or are WT (Figure 4).53 Because of the limited
number of patients included in the analysis, such results should be considered with caution
and will have to be confirmed in further studies. In addition, using free imatinib levels
derived from a per-sample analysis in these two Swiss analyses by Widmer and colleagues
may have led to an over-powered analysis, as this method ignores intra-patient
correlation.42,53 Extrapolation of free concentrations also still remains to be confirmed
formally by direct measurement of free plasma levels of imatinib in patients’ blood. Further
studies are also required to ascertain whether reproducible PD differences exist between
subgroups of patients with different KIT mutations and to identify minimum effective
concentrations for these subgroups.
Results from the French Database
The French database for imatinib BLT includes patients from BFR14, and Bui and
colleagues again demonstrated significant inter-patient variability in imatinib trough
levels.52 However, in contrast to earlier findings by Widmer and colleagues, this study
found that imatinib Cmin levels among GIST patients tended to be lower than trough levels
among CML patients, suggesting more rapid clearance in the GIST patient population.22,42
Other preliminary results from Bui and coworkers showed that long-term survivors tended
to have higher imatinib trough concentrations than more recently treated patients (Figure 5).
Nevertheless, no definitive conclusions concerning trough levels and long-term survival can
be made at this time.52
ADHERENCE WITH IMATINIB
Because imatinib therapy requires daily administration, maintaining proper adherence may
take on a greater significance in patients with GIST, as discontinuation of imatinib is
associated with loss of remission and a shorter time to relapse, even in patients who have
achieved CR when imatinib is discontinued. This is supported by the Phase III French
Sarcoma Group BFR14 Study evaluating the effect of imatinib interruption in responding
patients (CR, PR, or SD) after different periods of treatment.16,56,57 Three-and 5-year results
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from the study indicate that discontinuation of imatinib is associated with rapid
progression.56 Conversely, in CML, early studies showed that discontinuation of imatinib
may be feasible after sustained complete molecular response has been achieved, especially
in those pretreated with interferon.17 Yet, discontinuation of imatinib has been associated
with relapse in some patients with CML; however, previous best responses can be achieved
following imatinib re-introduction.58 Results obtained after discontinuation of imatinib in
CML are not fully concordant; nevertheless, continuous administration may be appropriate
for most patients. Better adherence appears also to be associated with significantly lower
resource utilization and costs in CML patients.59
Oral cancer therapies, such as imatinib, have become increasingly common in oncology
practice. Although these therapies offer patients the convenience of self-administration at
home, evidence suggests that adherence to oral cancer therapies is far from optimal.60–62 For
example, in one study, drug serum level monitoring revealed that patients with hematologic
cancers overestimated their compliance with allopurinol by a factor of two.60 Serum
samples showed that the control group (baseline levels of compliance) were fully compliant
16.8% of the time, whereas patient self-reports showed a compliance rate of 53.8%.
Evidence for suboptimal adherence with imatinib therapy
A number of recent studies have examined adherence to imatinib therapy among patient
populations with either GIST or CML; all documented surprisingly high rates of non-
adherence.61–63 Results from one study by Tsang and colleagues indicated that adherence to
imatinib declines markedly with time on therapy.62 Researchers tracked patient prescription
data for 4043 patients receiving imatinib for CML or GIST for 24 months. The study
evaluated compliance, defined as the dose of imatinib taken versus the dose prescribed, and
persistency, defined as the time in days that each patient remained on therapy. The overall
rate of compliance for both patient groups was 75% (78% in CML and 73% in GIST
patients). Total (100%) compliance was achieved by only half of the patients. During the
course of the 24-month study, average persistency was 255 days. As seen in other disease
categories in which adherence has been studied, the authors found a high and stable level of
persistency early in the treatment course, followed by a steady decline (Figure 6).62
Another study by Feng and coworkers examined prescription data for 320 patients who
received imatinib therapy for CML or GIST during a period of 12 months. The average rate
of full compliance was 76%. More than a quarter of patients (28%) interrupted therapy for at
least 30 consecutive days.61
The Adherence Assessment with Glivec®: Indicators and Outcomes (ADAGIO) study was
an observational, open-label trial conducted in 169 patients with CP CML who received
imatinib.63 Levels of non-adherence were examined using structured patient interviews,
intuitive ratings by patients and physicians, and pill counts. The study found that
approximately one-third of patients exhibited non-adherent behavior. Patterns of under- and
overtaking medication were evident using pill-count data, with perfect adherence reported in
only 14.2% (23/162) of patients.
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Factors contributing to non-adherence
Factors associated with non-adherence in the study conducted by Feng and colleagues
included increasing age (older than 51 years), gender (female), higher number of
concomitant medications, and complications of disease or therapy.61 In the ADAGIO study,
factors associated with non-adherence to imatinib therapy included increased age, increased
time since diagnosis, increased duration of imatinib treatment, and improved health at study
enrollment.63 Several other factors are recognized as important contributors to non-
adherence with drug therapy, including lack of understanding of the importance of
adherence to achieving and maintaining response; drug-related side effects;
miscommunication between the patient and physician; environment-related factors, such as
social, family, and patient attitudes toward treatment, as well as financial constraints; and
presence of cognitive impairments or psychopathologies.64
THERAPEUTIC DRUG MONITORING IN THE MANAGEMENT OF GIST
Blood level testing to maintain defined therapeutic drug levels is not commonly used in
oncology at present. However, it is employed for this purpose in several other medical
disciplines, including organ transplant, cardiology, neurology, psychiatry, and infectious
disease (especially in HIV/AIDS, a disease with a pharmacotherapeutic model that roughly
resembles GIST and CML). BLT is generally termed “therapeutic drug monitoring” in these
settings.65
Findings from recent studies have improved our understanding of the relationship between
imatinib exposure and clinical outcomes, but the putative plasma threshold for clinical
benefit for patients with GIST remains a subject of investigation. Nevertheless, drug level
monitoring in certain clinical situations as a mean of preventing low drug exposure has
proven valuable, giving the health care provider a tool for identifying patients with
suboptimal drug exposure so that possible causes can be investigated. PK/PD results from
the B2222 substudy have provided initial data for defining optimal plasma levels for
imatinib in GIST: plasma imatinib concentrations greater than 1100 ng/mL may increase the
likelihood of durable disease control. Imatinib blood concentrations lower than this level
may warrant investigation into possible causes of low drug exposure. The utility of imatinib
BLT for ensuring optimal drug exposure has already been suggested in CML.66,67
Practical issues in BLT
Current applications for BLT during imatinib therapy include lack of therapeutic response,
severe toxicities, drug–drug interactions, and non-adherence. BLT may also be important in
patients who have undergone major gastrectomy, to ensure optimal treatment with
imatinib.26 The potential role of BLT in optimizing therapeutic response is still
investigational, however, despite preliminary estimates of minimum imatinib blood levels
that correlate with improved clinical outcomes (Cmin >1110 ng/mL).5 However, threshold
blood levels at trough remain to be prospectively and retrospectively evaluated in larger
studies and defined for each major GIST mutational subtype. Further studies also may help
determine whether a correlation exists between suboptimal exposure and the development of
resistance. The correlation of imatinib blood levels with surrogate disease markers, blood
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cell counts, and phosphate levels may be useful in guiding therapy, particularly in the
adjuvant setting. Other areas of investigation include the predictive value of imatinib free
concentrations compared with total imatinib concentrations, the relationship between
imatinib blood and tissue levels, the relationship between blood levels and the portion of the
intestinal tract resected, and the importance of pharmacogenetic factors in drug exposure.
Further explorations of concentrations–toxicity relationship are also warranted. Moreover,
the development of mathematical algorithms will enable the drawing of samples at time
points not strictly corresponding to the trough level, thus, providing a wider sampling
window.68 However, current recommendations proposed by Wang and colleagues for
imatinib sampling are 24 hours post-dose for imatinib 400 mg daily dosing and 12 hours
postdose for imatinib 400 mg twice-daily dosing. Finally, the sampling tube required may
depend on the laboratory involved in the measurement.
Imatinib blood level testing in the French database study revealed that attaining good
adherence was problematic: the authors concluded that in four of seven patients who had
very low trough levels, poor adherence played a role.52. Although non-adherence appears to
be a significant problem with oral cancer treatments such as imatinib, drug monitoring can
be useful in detecting suspected cases of non-adherence, hopefully avoiding prolonged
suboptimal responses by ensuring minimal therapeutic plasma levels of imatinib.52
Although BLT may be useful, it is important to consider that measured drug blood levels are
indicative only of short-term compliance and may not reflect adherence during any
prolonged period prior to testing. Also, BLT may indeed be subject to a confounding “white
coat” effect when used to assess adherence.69
Major cancer treatment centers in Europe, in collaboration with the manufacturer of
imatinib, have developed a testing protocol for monitoring plasma levels in cancer
patients.70 This effort is focused on developing a database of imatinib plasma level
measurements to verify therapeutic plasma thresholds in various indications and to identify
and certify laboratories to provide proper testing services. Certification of testing
laboratories is done by a designated central laboratory, which implements a cross-check of
results to ensure consistency with testing standards. Additionally, the central laboratory
administers a system of regular quality-control checks.
The currently preferred analytical method used for imatinib BLT is liquid chromatography–
tandem mass spectrometry (LC-MS/MS). It provides a rapid, efficient, and simple means of
quantifying imatinib in plasma.71 The method has been shown to be precise, sensitive, and
accurate. LC-MS/MS assays are presently being developed to cover other major TKIs.72,73
Although LC-MS/MS is the preferred method for imatinib BLT, cost considerations may
prohibit its use in certain settings. High-performance liquid chromatography–ultraviolet
techniques have also been published, making the assay accessible by any laboratory or
institute not equipped with sophisticated and costly LC-MS/MS apparatus.74,75
In addition to its usefulness in optimizing exposure to imatinib, BLT may also serve the
same purpose with newer TKIs. Second-line agents such as sunitinib (Sutent®; Pfizer Inc;
New York, NY) and other investigational, newer-generation TKIs, for example, nilotinib
(Tasigna®; Novartis Pharma AG) and dasatinib (Sprycel®; Bristol-Myers Squibb; New
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York, NY), have been shown to be useful in patients who are intolerant/resistant to imatinib
and/or sunitinib.76–78 BLT may be applicable to these agents, but clinical PK/PD analyses
correlating efficacy with drug exposure as have been done with imatinib are still lacking.
CONCLUSIONS
Long-term studies of imatinib have documented impressive rates of response and survival.
Nevertheless, achieving optimal clinical benefit from imatinib depends on optimal dosing
and good adherence. Exposure to imatinib and subsequent impact on therapeutic benefit can
be affected by factors such as individual patient variability in absorption, distribution, and
metabolism, because of genetic or demographic differences, or because of anatomical or
GIST-related surgery abnormalities of the GI tract. Other specific factors, such as drug
interactions or environmental influences may also have an impact on drug exposure, thus
compromising response.
BLT may be useful in predicting and optimizing therapeutic response. Data from some PK
studies indeed show that low plasma exposure is associated with a trend toward lower rates
of objective response and faster development of resistance or progressive disease. Although
retrospective analyses of data from the B2222 PK substudy have provided a preliminary
estimate of a minimum threshold blood level for imatinib in GIST (1100 ng/mL),
convincing results from prospective studies are needed before BLT becomes a routine part
of imatinib therapy for patients with GIST. Furthermore, these studies would also help
determine suitable blood levels for different patient subgroups (in term of minimal, as well
as maximal levels). To that purpose, in CML, a randomized controlled trial (Imatinib
COncentration Monitoring Evaluation study) has just started in Europe.79 For GIST, studies
such as the Sarcoma Alliance for Research through Collaboration (SARC) Imatinib BLT
Study (SARC-019)80 may provide clearer, more definitive answers.
Monitoring imatinib blood or plasma levels appears to be a useful tool for investigating
cases of suboptimal therapeutic response, potential drug–drug interactions, toxicities that are
unusually severe for the dose of imatinib taken, and suspected non-adherence. A low blood
level may indeed provide health care providers with a means of initiating a discussion of the
importance of adhering to imatinib as prescribed. Establishing a baseline imatinib trough
level 1 month after treatment initiation could serve as a reference point for later
measurements, and it may help guide optimal imatinib blood levels throughout treatment in
cases of clinical concern. The outcome of ongoing prospective trials will be necessary for
clinicians to define the exact role of BLT for imatinib and other TKI treatment optimization.
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SEARCH STRATEGY AND SELECTION CRITERIA
A non-biased search of the chronic myelogenous leukemia and gastrointestinal stromal
tumors literature was performed, and pertinent articles identified on PubMed were
considered. References listed in relevant articles were searched as well. Abstracts and
reports from meetings were included only when they related directly to previously
published work. Only papers published in English were included.
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Figure 1. Imatinib exposures and expected concentrations
Predicted from a population PK model in GIST patients receiving imatinib 400 mg or 800 mg (400 mg bid) daily, the percentile
curves quantify expected dispersion for individual drug levels. With 400 mg qd, 25% of patients attain Cmin >1100 ng/mL (top
panel). With 400 mg bid, >90% of patients exceed this threshold (bottom panel). Curves were drawn from previously published
PK data.22
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Figure 2. Effects of albumin (ABL) and WBC on model predicted AUC∞ Day 1 and single-dose AUC24 at steady state (Day 29)
5
 Plasma albumin and WBC counts were the only two significant PK covariates identified for imatinib clearance and volume of
distribution in the B2222 PK substudy.
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Figure 3. Distribution of patients by imatinib Cmin level at steady state (Day 29)
5
 Vertical lines represent 25% and 75% percentiles. 400 mg group (n=34): 11 patients are in quartile 1 (Q1), 16 in Q2–Q3, and 7
in Q4. 600 mg group (n=39): 7 patients are in Q1, 20 in Q2–Q3, and 12 in Q4.
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Figure 4. Free imatinib trough levels (Cmin) according to therapeutic response in exon 9 mutated or WT KIT patients
53
 Box plots and individual values of free Cmin: responders were complete response, partial response, or stable disease; n=14;
median = 25.7 ng/mL. Non-responders were progressive disease; n=19; median = 10.1 ng/mL.
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Figure 5. French database: imatinib Cmin according to time under treatment
52
 Results from French Database showing that long-term survivors tend to have higher imatinib concentrations compared with
those who had initiated treatment more recently.
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Figure 6. Imatinib adherence
62
 Higher and stable level of persistency through Month 4 followed by a steady decline in adherence.
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Table 1
Study B2222: Imatinib pharmacokinetic parameters at steady state.5
Parameters 400 mg qd
Mean ± SD (CV%)
(n=34)
600 mg qe
Mean ± SD (CV%)
(n=39)
AUC, µg*hr/mL 56.4 ± 23.9 (42.5%) 64.3 ± 27.1 (42.2%)
Cmax, ng/mL 3405 ± 1434 (42.1%) 3868 ± 1574 (40.7%)
Cmin, ng/mL 1530 ± 666 (43.6%) 1752 ± 794 (45.3%)
CL/F, L/hr 8.84 ± 4.87 (55.1%) 10.9 ± 4.43 (40.6%)
T1/2, hr 19.3 ± 2.2 (11.5%) 19.5 ± 2.8 (14.3%)
qd, once daily; SD, standard deviation; CV%, percentage coefficient of variation.
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Table 2
Response and time to progression by imatinib Cmin quartile.5
PK Cmin quartiles (n=73)
Response Q1 (n=18)
n (%)
Q2–Q3 (n=36)
n (%)
Q4 (n=19)
n (%)
CR + PR + SD* 12 (67) 29 (81) 16 (84)
CR + PR† 8 (44) 24 (67) 14 (73)
Median TTP, months‡ 11.3 30.6 33.1
*Chi-square test comparing two groups: Cmin <Q1 vs Cmin ≥Q1; P=0.177;
†Chi-square test comparing two groups: Cmin <Q1 vs Cmin ≥Q1; P=0.0601;
‡
P=0.0105 and P=0.0029 between Q1 and Q2–Q4, hazard ratio=0.418 with 95% CI (0.231, 0.756).
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Table 3
Overall objective clinical benefit (CR+PR+SD) by imatinib Cmin quartile for KIT exon 11 patients.5
PK Cmin Quartiles (n=39)
Response Q1 (n=9)
n (%)
Q2–Q3 (n=17)
n (%)
Q4 (n=13)
n (%)
CR + PR + SD 6 (67) 17 (100) 13 (100)
Chi-square test comparing two groups: Cmin <Q1 vs Cmin ≥Q1; P=0.009.
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